Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Binding Mechanism of UAMC-1110 to Fibroblast Activation Protein.

Journal of chemical information and modeling·2026
Same author

Ferroptosis inhibition enhances liver and lung graft function.

Cell·2026
Same author

Vectorized ULK1/2 and VPS34 Inhibitors for Tissue-Selective Autophagy Inhibition in Oncology.

Journal of medicinal chemistry·2026
Same author

In vitro kinetic profiling by enzymatic approaches to select FAPIs with a long residence time.

European journal of medicinal chemistry·2025
Same author

C2PO: an ML-powered optimizer of the membrane permeability of cyclic peptides through chemical modification.

Journal of cheminformatics·2025
Same author

MolAgent: Biomolecular Property Estimation in the Agentic Era.

Journal of chemical information and modeling·2025
Same journal

Residue-level insights into SGLT2 inhibition and Nav1.5 selectivity of gliflozin derivatives: A molecular dynamics and pharmacophore-guided study.

Journal of molecular graphics & modelling·2026
Same journal

A benchmarking-informed structure-based virtual screening strategy targeting Lm-PTR1: Leveraging the Northern African natural products database.

Journal of molecular graphics & modelling·2026
Same journal

In Silico identification of natural and synthetic inhibitors targeting KRAS mutants (G12D, G12V, and G12C) and wild-type in pancreatic cancer.

Journal of molecular graphics & modelling·2026
Same journal

Structural evolution, mechanical and thermal stability of 7-40 mol% yttria-stabilized zirconia: First-principles investigation.

Journal of molecular graphics & modelling·2026
Same journal

Halide-encapsulated C<sub>24</sub> fullerenes as molecular redox hosts for alkali metals: A density functional theory study.

Journal of molecular graphics & modelling·2026
Same journal

Efficacy of Tinospora cordifolia bioactives as agonists of Smoothened (Smo) receptor to promote oligodendroglial lineage induction for remyelination-based therapy.

Journal of molecular graphics & modelling·2026
See all related articles

Related Experiment Video

Updated: Jul 5, 2026

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

Pharao: pharmacophore alignment and optimization.

Jonatan Taminau1, Gert Thijs, Hans De Winter

  • 1Silicos NV, Wetenschapspark 7, B-3590 Diepenbeek, Belgium. hans.dewinter@silicos.com

Journal of Molecular Graphics & Modelling
|May 20, 2008
PubMed
Summary
This summary is machine-generated.

A new tool called Pharao uses Gaussian volumes to model molecular features for drug discovery. This approach improves the scoring and alignment of small molecules, aiding in virtual screening and ligand clustering.

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Related Experiment Videos

Last Updated: Jul 5, 2026

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Area of Science:

  • Computational chemistry
  • Drug discovery
  • cheminformatics

Background:

  • Accurate scoring and alignment of small molecules are crucial in early drug discovery.
  • Existing pharmacophore models often use discrete points or spheres, which can limit optimization.
  • Developing novel computational tools is essential for efficient lead identification.

Purpose of the Study:

  • To introduce Pharao, a novel pharmacophore-based tool for scoring and aligning small molecules.
  • To demonstrate the utility of Gaussian 3D volumes for representing pharmacophoric features.
  • To evaluate Pharao's performance in virtual screening and ligand clustering tasks.

Main Methods:

  • Pharmacophore modeling using Gaussian 3D volumes.
  • Development of an alignment optimization algorithm leveraging continuous functions.
  • Application of Pharao for virtual screening of trypsin and phosphodiesterase 5 inhibitors.
  • Unsupervised clustering of small molecules based on Pharao-derived features.

Main Results:

  • Pharao effectively models pharmacophoric features using continuous Gaussian volumes.
  • The smooth nature of Gaussian volumes facilitates the alignment optimization process.
  • Pharao demonstrated utility in virtual screening tasks for specific enzyme targets.
  • Pharao-based clustering revealed biologically relevant groupings of small ligands.

Conclusions:

  • Pharao offers a robust and efficient method for small molecule scoring and alignment in drug discovery.
  • The Gaussian volume approach provides advantages over traditional point/sphere representations.
  • Pharao is a valuable tool for enhancing virtual screening and understanding ligand-target interactions.